| Literature DB >> 34222434 |
Yan Tian1, Xiao-Xin Li2, Jiao-Jiao Zhang2, Qing Yun2, Si Zhang2, Jia-Yi Yu2, Xue-Jiao Feng2, Ai-Ting Xia2, Yang Kang3, Feng Huang2, Fang Wan2.
Abstract
BACKGROUND: Keratosis pilaris is a hereditary abnormal keratosis of the hair follicle orifice. Gray-brown keratotic plugs in the pores and dark red keratotic papules at the openings of hair follicles can be seen, which contain coiled hair and are often accompanied by perifollicular erythema and pigmentation. Glycolic acid can correct the abnormalities of hair follicular duct keratosis and eliminate excessive accumulation of keratinocytes. It also promotes skin metabolism and accelerates the melanin metabolism. The therapeutic effect is related to the glycolic acid concentration. AIM: To evaluate the efficacy and safety of a high concentration of glycolic acid in the treatment of keratosis pilaris, and to observe the outcomes at 5-year of follow-up.Entities:
Keywords: Follicular erythema; Glycolic acid; Keratosis pilaris; Keratotic papules; Melanin pigmentation
Year: 2021 PMID: 34222434 PMCID: PMC8223817 DOI: 10.12998/wjcc.v9.i18.4681
Source DB: PubMed Journal: World J Clin Cases ISSN: 2307-8960 Impact factor: 1.337
Global esthetic improvement scale
|
|
|
| Excellent improvement | The best aesthetic results are achieved after treatment |
| Significant improvement | There is significant improvement in appearance compared to the initial situation |
| Some improvement | Compared with the initial situation, there is obvious improvement |
| No improvement | The appearance is essentially the same as the initial situation |
| Worse | The appearance is worse than the initial situation |
Changes in the number of keratotic papules before and after treatment of the 25 study cases
|
|
|
|
|
|
|
| 1 | 52 | 25 | 20 | 16 | 10 |
| 2 | 26 | 22 | 21 | 15 | 14 |
| 3 | 95 | 80 | 71 | 58 | 28 |
| 4 | 46 | 38 | 32 | 25 | 24 |
| 5 | 58 | 49 | 33 | 29 | 21 |
| 6 | 35 | 23 | 19 | 14 | 10 |
| 7 | 80 | 58 | 43 | 37 | 26 |
| 8 | 66 | 47 | 58 | 23 | 19 |
| 9 | 35 | 21 | 18 | 15 | 11 |
| 10 | 75 | 59 | 50 | 38 | 36 |
| 11 | 38 | 25 | 16 | 15 | 12 |
| 12 | 43 | 37 | 33 | 26 | 13 |
| 13 | 55 | 53 | 48 | 43 | 42 |
| 14 | 61 | 30 | 22 | 15 | 11 |
| 15 | 48 | 45 | 41 | 31 | 25 |
| 16 | 57 | 55 | 51 | 45 | 43 |
| 17 | 39 | 33 | 28 | 21 | 14 |
| 18 | 72 | 65 | 55 | 43 | 37 |
| 19 | 28 | 22 | 19 | 12 | 7 |
| 20 | 30 | 27 | 21 | 16 | 12 |
| 21 | 42 | 38 | 33 | 27 | 23 |
| 22 | 58 | 53 | 45 | 37 | 29 |
| 23 | 65 | 62 | 57 | 49 | 33 |
| 24 | 36 | 29 | 23 | 16 | 9 |
| 25 | 88 | 80 | 66 | 52 | 45 |
| Average | 53.12 ± 18.49 | 43.04 ± 17.53 | 36.92 ± 16.24 | 28.72 ± 13.51 | 22.16 ± 11.61 |
Data are the number of keratotic papules before treatment and on days 20, 40, 60, and 80.
Figure 1Effectiveness of keratotic papule treatment. A: Day 20 of treatment; B: Day 40 of treatment; C: Day 60 of treatment; D: Day 80 of treatment. CI: Complete improvement; EI: Excellent improvement; ER: Effective rate; NI: No improvement; SI: Some improvement.
Figure 2Therapeutic outcomes of a representative subject. A: Pretreatment; B: Day 20 of treatment; C: Day 40 of treatment; D: Day 60 of treatment; E: Day 80 of treatment.
Changes in melanin content, skin hemoglobin content, and skin lightness before and after treatment
|
|
|
|
|
|
|
|
| M value | 219.48 ± 64.09 | 215.80 ± 63.87 | 213.12 ± 60.42 | 203.92 ± 58.62 | 197.04 ± 59.23 | 223.56 ± 45.51 |
| E value | 261.76 ± 60.31 | 256.16 ± 64.00 | 258.48 ± 67.86 | 248.36 ± 62.50 | 242.2 ± 66.39 | 255.13 ± 51.25 |
| L value | 61.41 ± 4.23 | 61.94 ± 4.17 | 62.20 ± 3.94 | 62.57 ± 3.78 | 63.24 ± 3.60 | 61.89 ± 3.83 |
P < 0.05 vs pretreatment. E: Skin hemoglobin content; L: Skin lightness; M: Melanin content.
Self-evaluation status of subjects
|
|
|
|
|
|
|
| Excellent improvement | 0 | 0 | 1 | 1 | 0 |
| Significant improvement | 2 | 4 | 5 | 7 | 0 |
| Some improvement | 9 | 11 | 12 | 11 | 3 |
| No change | 12 | 10 | 7 | 6 | 4 |
| Worse | 0 | 0 | 0 | 0 | 2 |
| Total | 25 | 25 | 25 | 25 | 9 |
Data are the number of subjects.